Please Tell Me You Saw (SXTP) Move Approx 156% This Morning

*Sponsored by 60 Degrees Pharmaceuticals, Inc. Just Announced! 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is Our Next Potential Breakout Idea… (SXTP) Comes Backed By Several Potential Catalysts Like: Razor Thin Float: There’s Only 1.5M shares in the float, which could set the stage for significant swing potential if demand begins to shift. Insider Confidence: CEO insider purchases highlight strong belief in the company’s future and growth prospects. Analyst Target: A $3.40 target suggests 165% upside potential from yesterday’s $1.28 open. (On 1/07/2025) Momentum Potential: An approximate 254% move in six weeks could signal a growing public interest. Keep reading to see why (Nasdaq: SXTP) is #1 on our  watchlist this morning… January 8, 2025 Dear Reader, Few sectors can match the growth potential seen in the disease treatment industry, where small companies with modest market caps can skyrocket practically overnight. When a company shows the potential for a significant breakthrough, it often grabs the spotlight and market attention. Which is exactly what we saw today with 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) moving approximately 156% before the opening bell even rang. The move comes on the heels of their announcement regarding the first patient enrollment in an expanded access clinical study evaluating tafenoquine for persistent babesiosis. This critical study targets a high-risk patient population with limited treatment options, underscoring SXTP’s leadership in addressing a growing unmet medical need. Not only did SXTP achieve a remarkable pre-market move from $1.405 to $3.60, but it also shattered key moving averages, including: 5-day (1.3260) 20-day (1.4360) 50-day (1.1469) 100-day (1.2278) 200-day (2.0483)  Keep this one on your radar.  If you missed my earlier email, keep reading below to get caught up to speed.  A low-float company we’ve covered before—one that moved approximately 20% in just a few hours last time—has reappeared on our radar. Say hello to 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP), a leader in one of our favorite sectors, Biotech, and a name that’s impossible to ignore. Here’s why (SXTP) is #1 on our watchlist today: Razor-thin float: Only 1.5M shares, creating the potential for significant swings. Analyst target: A $3.40 price target pointing to 165% upside potential. Building momentum: An approximate 254% move in about six weeks shows growing public interest. Strong intellectual property: Over 40 patents solidify its innovation edge. Insider confidence: Benzinga recently reported (SXTP)’s CEO was buying shares. Bullish technical signals: 15 Bullish Signals on TradingView’s tools, including the Momentum Indicator. We saw it coming before, and we’re seeing it again now.  Now let’s dive into why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is topping our watchlist this morning.  In the fast-paced world of biotech and pharma breakthroughs, few companies push boundaries with the confidence and expertise of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP). With a sharp focus on solving critical unmet needs in infectious diseases, 60P has built an impressive portfolio fueled by cutting-edge science and an unrelenting drive to make an impact. From redefining malaria prevention to advancing treatments for tick-borne illnesses like babesiosis, this company isn’t just competing—it’s setting the standard for innovation, market expansion, and global influence. A Game-Changer in Malaria Prevention ARAKODA® (tafenoquine), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s flagship product, is a revolutionary antimalarial therapy that earned FDA approval in 2018 and became commercially available the following year.  Unlike other treatments, ARAKODA® provides complete protection against all stages of malaria with a convenient weekly dosing schedule—no resistance, no hassle.  Its unique attributes, including broad-spectrum activity, have earned recommendations from the CDC and cemented its reputation as the top choice for malaria prophylaxis. With a $50–$70 Mln U.S. market for malaria prevention alone, ARAKODA® has already established a foothold in a critical space, showing consistent sales growth.  And let’s not overlook the bigger picture: a global burden of 249 Mln malaria cases annually underscores the dire need for solutions like ARAKODA®. Expanding Horizons: Tackling Tick-Borne Diseases Not content with its success in malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is charging ahead in the treatment of babesiosis, a tick-borne disease on the rise in the U.S.  The company has launched pivotal trials for acute babesiosis and plans to address chronic cases next.  FDA orphan status for tafenoquine highlights its potential as the only game in town for a disease where existing treatments lack efficacy. Babesiosis isn’t just a public health issue—it’s a market with significant potential. With up to 1 Mln chronic cases in the U.S. and growing acute incidence rates, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is positioning itself to dominate this emerging space, potentially expanding its patient reach to over 2 Mln. Strong Intellectual Property Portfolio A critical driver of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s success is its robust and expanding intellectual property portfolio.  The company holds three Orange Book-listed patents for tafenoquine, protecting its malaria prevention innovations until 2035.  With 42 additional patents filed, pending, or optioned across multiple therapeutic areas—including tick-borne diseases and respiratory viruses—60P is playing a long game, ensuring market exclusivity and driving future growth. A Leadership Team That Delivers Behind this powerhouse is a leadership team with unmatched experience and credentials. CEO Geoffrey Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.  Chief Medical Officer Bryan Smith, with 30+ years of clinical expertise, brings unparalleled insight into pharmacovigilance and regulatory strategy.  And let’s not forget Chief Commercial Officer Kristen Landon, who has launched more than a dozen blockbuster brands, driving revenues well into nine figures. This team isn’t just talking the talk—they’re walking the walk, executing on ambitious plans to scale commercial operations and meet aggressive pro-fit-ability targets by Q4 2026. Evolving Strategies for Commercial Growth 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s commercial strategy for ARAKODA® is razor-sharp: differentiate it from generic competitors with a compelling value story, expand its use among healthcare providers, and reduce access barriers through co-pay assistance programs.  This targeted approach has already shown results, with organic sales growth reflecting increased awareness among prescribers in the Lyme disease community. And it doesn’t stop there.  The company’s forward-looking pipeline includes Celgosivir, targeting dengue and respiratory viruses, and an exploratory program for canine babesiosis, hinting at diversification into veterinary markets. Fiscal Momentum and Milestones Ahead The numbers don’t lie. Recent rounds have injected over $5.9M into 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s coffers, enabling critical funding in commercialization and clinical development.  With three babesiosis trials underway, the company is poised to deliver interim results by early 2026—just in time to accelerate its push toward pro-fit-ability. Upcoming potential catalysts include sales growth milestones, new product development collaborations, and regulatory submissions.   If history is any guide, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) isn’t just checking boxes; it’s carving out its place in the biotech space. The Bottom Line 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is more than a pharma company—it’s a force to be reckoned with in the fight against infectious diseases.  With groundbreaking products, a visionary leadership team, and an aggressive roadmap for growth, (SXTP) is redefining what’s possible in this space.  For those watching closely, one thing is clear: this company doesn’t just participate—it dominates. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is drawing attention with several potential catalysts that could help drive its momentum.  With a razor-thin float of only 1.5M shares, the company is positioned for potential market movements.  Recent insider purchases by the CEO reflect confidence in its direction, while a 165% upside target points to notable growth potential. The company has recently witnessed an approximate 254% move in six weeks, which could be an indicator of growing market interest.  As of midday, yesterday (1/7/2025), (SXTP) was triggering 15 Bullish Signals on TradingView’s technical analysis tool using the 15 minute time-frame.  Coupled with a robust intellectual property portfolio of over 40 patents, the company is positioning itself to advance its efforts in addressing unmet medical needs.  These elements create a compelling case for keeping an eye on this emerging biotech player. In Recent News… 60 Degrees Pharmaceuticals  and Tufts MC Partner to Advance Babesiosis Treatment 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) and Tufts Medical Center have partnered to advance tafenoquine for babesiosis treatment and prevention through a new Patent License Agreement.  This collaboration grants (SXTP) exclusive global rights to develop and commercialize tafenoquine, while Tufts MC retains research licenses and earns royalties from future product sales. Building on ongoing trials at institutions like Tufts MC and Yale, the partnership aims to position tafenoquine as the first prophylactic treatment for babesiosis, addressing a critical unmet need.  CEO Geoff Dow, PhD, emphasized the shared confidence in tafenoquine’s potential to provide effective solutions for this growing public health challenge. 5 Reasons Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)  is #1 On Our Watchlist Tomorrow… 1. Razor-Thin Float and Momentum: With just 1.5M shares in the float and an approximate 254% move in six weeks, demand shifts could drive the potential significant swings if public interest grows. 2. Insider and Analyst Confidence: Recent insider purchases by the CEO signal strong belief in the company’s future, while an analyst target of $3.40 suggests a 165% upside potential from recent levels. 3. Robust Intellectual Property: With over 40 patents, including three Orange Book-listed patents for its FDA-approved malaria treatment, the company has secured long-term innovation and market exclusivity. 4. FDA-Approved Product: ARAKODA®, the company’s flagship product, is FDA-approved and addresses a $50–$70M U.S. malaria prevention market while also targeting global health needs. 5. Expanding Pipeline: Pivotal trials for tick-borne diseases and chronic illnesses position the company as a key player in emerging medical markets, ensuring long-term growth potential. Consider Adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to Your Radar This Week… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has all the hallmarks of a biotech worth paying attention to. With an ultra-low float of just 1.5M shares, the potential for significant market movement is clear.  Insider confidence is evident with recent CEO purchases, while Lucas Ward, an analyst at Ascendiant Capital Markets, recently set a $3.40 target on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) which suggests 165% upside potential underscores the growth potential from today’s opening level of around $1.28. The company’s potential momentum appears to be already building, with an approximate 254% move in six weeks, signaling what could be a growing public interest.  Its robust intellectual property portfolio of over 40 patents, combined with the FDA-approved ARAKODA®, places it in a strong position to capitalize on the $50–$70M U.S. malaria prevention market and address critical global health challenges. Looking ahead, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is not just relying on its success in malaria; its expanding pipeline targeting tick-borne diseases and chronic illnesses demonstrates its commitment to innovation and long-term growth.  This is a company with the vision, leadership, and foundation to make a meaningful impact in the biotech sector. Remember, (SXTP) only has 1.5M shares listed in the public float, with a recent analyst target suggesting 165% in potential upside.  As of midday, yesterday (1/07/2025), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) was triggering 15 Bullish Signals, including the momentum indicator. We’ll have all eyes on (SXTP) this morning so keep a lookout for my next update. Remember, the last time we covered (SXTP) it moved approximately 20% in just a few hours.  Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and 60 Degrees Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, we have been paid fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one hundred forty-nine thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US). Neither TD Media LLC or its member owns shares of (SXTP:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/sxtp/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice